ADC Therapeutics to Present at November Investor Conferences

Rhea-AI Summary

ADC Therapeutics (NYSE: ADCT) will present at three investor conferences in November 2025 with CEO Ameet Mallik participating in each session.

Schedule:

• Stephens Biotechnology Virtual Fireside Chats – Nov 3, 2025 at 12:00 p.m. ET (virtual; no replay or transcript)
• Guggenheim Second Annual Healthcare Innovation Conference – Nov 11, 2025 at 1:30 p.m. ET (Boston; live webcast available)
• Jefferies Global Healthcare Conference – Nov 19, 2025 at 12:30 p.m. GMT (London; live webcast available)

Live webcasts for Guggenheim and Jefferies will be available on the company’s Events & Presentations page at ir.adctherapeutics.com, and replays will be available for approximately 30 days after each event.

LAUSANNE, Switzerland, Oct. 27, 2025 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced participation in three upcoming investor conferences in November:

Stephens Biotechnology Virtual Fireside Chats 2025
Date: November 3, 2025
Presentation Time: 12:00 p.m. ET
Format: Fireside Chat
Speaker: Ameet Mallik, Chief Executive Officer
Location: Virtual
There will not be a replay or transcript of the call. To join the meeting or to obtain more information, please contact your Stephens representative.

Guggenheim Second Annual Healthcare Innovation Conference 
Date: November 11, 2025
Presentation Time: 1:30 p.m. ET
Format: Fireside Chat
Speaker: Ameet Mallik, Chief Executive Officer
Location: Boston, MA
To register for the webcast, click here.

Jefferies Global Healthcare Conference
Date: November 19, 2025
Presentation Time: 12:30 p.m. GMT
Format: Fireside Chat
Speaker: Ameet Mallik, Chief Executive Officer
Location: London, England
To register for the webcast, click here.

Live webcasts of the Guggenheim and Jefferies presentations will be available via the Events & Presentations page in the Investors section of ADC Therapeutics' website, ir.adctherapeutics.com. A replay of each webcast will be available for approximately 30 days following each event.

About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), transforming treatment for patients through our focused portfolio with ZYNLONTA (loncastuximab tesirine-lpyl) and an early stage PSMA-targeting ADC.

ADC Therapeutics' CD19-directed ADC ZYNLONTA received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics is leveraging its expertise to advance IND-enabling activities for a next-generation PSMA-targeting ADC which utilizes a differentiated exatecan-based payload with a novel hydrophilic linker.

Headquartered in Lausanne (Biopôle), Switzerland, with operations in London and New Jersey, ADC Therapeutics is focused on driving innovation in ADC development with specialized capabilities from clinical to manufacturing and commercialization. Learn more at adctherapeutics.com and follow us on LinkedIn.

Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the success of the Company's strategic restructuring plan; changes in estimated costs associated with the restructuring plan including the workforce reduction and planned closure of the UK facility; the expected cash runway into 2028 which assumes use of minimum liquidity amount required to be maintained under its loan agreement covenants; whether future LOTIS-7 clinical trial results will be consistent with or different from the LOTIS-7 data presented at EHA and ICML and future regulatory and compendia strategy and opportunity; the timing of the PFS events for LOTIS-5 and the results of the trial and full FDA approval for ZYNLONTA®; future safety and efficacy results of the Phase 2 IIT in MZL and any regulatory or compendia pathways; the Company's ability to grow ZYNLONTA® revenue in the United States and potential peak revenue; the ability of our partners to commercialize ZYNLONTA® in foreign markets, the timing and amount of future revenue and payments to us from such partnerships and their ability to obtain regulatory approval for ZYNLONTA® in foreign jurisdictions; the timing and results of the Company's or its partners' research and development projects or clinical trials including LOTIS-5 and LOTIS-7, as well as early pre-clinical research for our exatecan-based ADC targeting PSMA; the timing and results of investigator-initiated trials including those studying FL and MZL and the potential regulatory and/or compendia strategy and the future opportunity; the timing and outcome of regulatory submissions for the Company's products or product candidates; actions by the FDA or foreign regulatory authorities; projected revenue and expenses; the Company's indebtedness, including Healthcare Royalty Management and Blue Owl and Oaktree facilities, and the restrictions imposed on the Company's activities by such indebtedness, the ability to comply with the terms of the various agreements and repay such indebtedness and the significant cash required to service such indebtedness; the Company's ability to obtain financial and other resources for its research, development, clinical, and commercial activities; and the uncertainties of international trade policies, including tariffs, sanctions and trade barriers and potential impact they may have on our business, financial condition, and results of operations. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K and in the Company's other periodic and current reports and filings with the U.S. Securities and Exchange Commission. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this document.

CONTACTS:
Investors and Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040

View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-to-present-at-november-investor-conferences-302594299.html

SOURCE ADC Therapeutics SA

FAQ

When will ADC Therapeutics (ADCT) present at the Stephens Biotechnology Virtual Fireside Chat?

ADC Therapeutics will present on Nov 3, 2025 at 12:00 p.m. ET; the session is virtual and there will be no replay or transcript.

How can investors watch ADC Therapeutics' (ADCT) Guggenheim conference presentation on Nov 11, 2025?

The Guggenheim presentation on Nov 11, 2025 at 1:30 p.m. ET will have a live webcast accessible via the company’s Events & Presentations page at ir.adctherapeutics.com.

What time is ADC Therapeutics (ADCT) speaking at the Jefferies Global Healthcare Conference in London?

The Jefferies presentation is scheduled for Nov 19, 2025 at 12:30 p.m. GMT; a live webcast will be available on the investor website.

Who will represent ADC Therapeutics (ADCT) at the November 2025 investor conferences?

Ameet Mallik, Chief Executive Officer, is listed as the speaker for all three November 2025 events.

Will replays be available for ADC Therapeutics (ADCT) November 2025 webcasts?

Yes. Replays of the Guggenheim and Jefferies webcasts will be available for approximately 30 days after each event; the Stephens session will not have a replay.

How do investors register to join ADC Therapeutics (ADCT) conference webcasts?

To join, use the registration links provided for each event or visit the company’s Events & Presentations page at ir.adctherapeutics.com for webcast access and registration details.